Press Release

Adaptive Biotechnologies and Collaborators to Highlight New immunoSEQ Data at AACR 2019


SEATTLE, WA, March 28, 2019 — Adaptive Biotechnologies and its collaborators will present 11 studies, including an oral presentation and 10 poster presentations, at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA, March 29 – April 3.

New data will demonstrate how immunosequencing at scale and with precision using Adaptive’s immunoSEQ® Assay may be used in clinical trials to predict overall survival and response to novel immunotherapies, such as checkpoint inhibitors and cancer vaccines, in solid tumors.  Other data will examine the ability of immunoSEQ to quantify and characterize the individual T cell receptors (TCR) of tumor infiltrating lymphocytes (TILs), a type of white blood cell that attacks cancer cells and controls tumor proliferation, to assist in identifying subtypes of colorectal cancer. This information may be used to help determine response to immunotherapy and patient outcomes among subtypes. Collectively the studies also demonstrate a growing use of immunoSEQ by academia and the pharmaceutical industry to help guide clinical research.

“Adaptive’s immune medicine platform is essential to helping our academic and pharmaceutical industry partners decode the information stored in our immune systems to answer translational research questions and discover new prognostic and diagnostic signals in oncology clinical trials,” said Chad Robins CEO and co-founder of Adaptive Biotechnologies. “Making this tool widely available to research partners helps us drive toward our goal of transforming medicine to improve patient lives.”

Abstracts are available on AACR website:!/6812.  immunoSEQ presentations of interest include:

  • Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma (abstract # 2272/1), poster presentation, April 1, 1:00 – 5:00 pm ET, Exhibit Hall B, Section 20
  • Tumor infiltrating lymphocytes, immunoSeq, and CMS classification in the molecular epidemiology of colorectal cancer study, (abstract #2332/1), poster presentation, April 1, 1:00 – 5:00 pm ET, Exhibit Hall B, Section 23
  • Detection of tumor T-cell clones in mediastinal lymph nodes is associated with lower risk of tumor progression (abstract #3175/28), poster presentation, April 2, 8:00 am – 12:00 pm ET, Exhibit Hall B, Section 21
  • Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy (abstract #3776/9), April 2 1:00 – 5:00 pm ET, Exhibit Hall B, Section 7

About immunoSEQ Assays

Adaptive’s immunoSEQ Assay helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assay can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, the immunoSEQ Assay is used to ask and answer translational research questions and discover new prognostic and diagnostic signals in clinical trials.  immunoSEQ Assay provides quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assay is for research use only and is not for use in diagnostic procedures.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune medicine platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases such as cancer, autoimmune conditions, and infectious diseases are diagnosed and treated. For more information, please visit



Adaptive Biotechnologies

Beth Keshishian (media)